Egypt Anal Fistula Therapeutics Market Report 2023 to 2030

Egypt Anal Fistula Therapeutics Market Analysis

$ 3999

Egypt During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.

ID: IN10EGRD004 CATEGORY: Rare Diseases GEOGRAPHY: Egypt AUTHOR: Nipun Arora

Buy Now

Egypt Anal Fistula Therapeutics Market Analysis Summary

Egypt Anal Fistula Therapeutics Market is valued at around $1.46 Mn in 2022 and is projected to reach $1.98 Mn by 2030, exhibiting a CAGR of 3.9% during the forecast period 2023-2030.

The inner wall of the anal hole is lined with mucous-secreting glands that facilitate stool passage. These glands can occasionally become infected, clog, and, like a pimple, quickly fill up with fluids and pus, causing swelling and agony. A term for this is an abscess. As pressure builds up inside, around half of the abscesses that develop in this area begin draining out through a recently developed tiny channel to the exterior. An anal fistula is what is created when this occurs. These can hurt and make you uncomfortable, and they can also cause bleeding when you pass stool. Mucous or faecal discharge may develop, and fistulous trajectories may form on either side of the anus (never in the midline). Skin irritation is possible around the external orifice. More commonly than women, men are affected. Inflammatory bowel diseases (IBD), such as ulcerative colitis and Chron's disease, are becoming more prevalent internationally, which is one of the key growth factors for the global anal fistula treatment market. Additionally, anal fistulas are becoming more common among patients, which fuels the market's expansion. The predicted recurrence rate ranges from 7 to 21 percent, depending on the type of fistula and the surgical technique used. For instance, fibrin glue frequently recurs. Anal fistulas frequently need to be treated because they won't heal on their own. Surgery is frequently advised for the treatment of anal fistulas.

Anal fistula medications include Prilocaine, Fentanyl, Adalimumab, Diclofenac, and analgesics. The leading industry players are developing cutting-edge drugs and equipment because there is a growing demand for safe, effective treatments with little chance of recurrence and fewer adverse effects. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.

Market Dynamics

Market Growth Drivers

The desire for safe, effective treatments with minimal risk of recurrence and fewer side effects is also increasing, which is driving the major industry players to produce cutting-edge medications and equipment. The development of anal fistula therapy through technology is accelerating market expansion. The creation of fresh surgical therapy choices and the booming rise of the medical tourism industry have aided in the sector's segment growth.

Market Restraints

Lack of patient awareness: It is critical for individuals to be aware of potential consequences so they can spot the warning signals early and seek medical help if necessary. This will enable prompt treatment for them and lessen the effect of the complication on their general health and well-being
High costs of treatment: The cost of treatment is subjectively high as it involves surgery and revisits to the doctor to ensure progress in recovery
The risk of infection and the need for hospitalization is another restraint in this market
Self-medication: other than antibiotics, patients overdosing on vitamins, zinc tablets, and herbal tonics exacerbated the symptoms of an existing fissure in the long run

Market Development

Advanced technologies being developed to minimize the recurrence rate of anal fistulae, such as adipose-derived stem cells therapy, video-assisted anal fistula treatment (VAAFT) devices, and laser energy-based devices for anal fistula open up new opportunities for the growth of the global Anal Fistula Treatment Market. Recently, a novel procedure, transanal opening of intersphincteric space (TROPIS), has shown a success rate of 79% to 90% in highly complex anal fistulas with minimal impact on continence. In March 2022, The FDA approved Ossium Health, Inc.’s application for OSSM-001, a mesenchymal stem cell (MSC) product, to be considered as an investigational new drug (IND) for the treatment of refractory perianal fistulas in Crohn’s disease patients.

In February 2022, Takeda published the first INSPIRE six-month interim analysis data, showing that 65% of patients in both cohorts who were assessed at six months had achieved clinical remission. The INSPIRE trial (EUPAS24267) is an observational, multicenter, post-approval, open-enrollment study conducted in Europe to assess the safety and efficacy of Alofisel (darvadstrocel) in patients with complicated perianal fistulas and Crohn’s disease (CD).

Key players

Shire Pfizer Sanofi Novartis Johnson & Johnson Baxter International Octapharma Kedrion Biotest Grifols

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Anal Fistula Therapeutics Market Segmentation

By Treatment

Surgical
- Fistulotomy
- Reconstructive surgery
- Seton
- Laser ablation of the fistula tract
Non- Surgical
- Fibrin glue
- Laxatives
- Antibiotics
- Topical Nitrates
- Calcium Channel Blockers
- OnabotulinumtoxinA Injections
- Others

By End User

Hospitals
Surgical centers
Clinics
Pharmacists
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.